miRNA profile of neuroprotection mechanism of echinomycin in Parkinson’s disease

Kwon, Daeho; Liew, Hyunjeong

doi:10.1007/s13273-017-0025-6

Cited by 8 publications

(2 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A titer of islet autoantibodies IAA was negatively associated with miR-10b-5p [ 122 ]. miR-200c-3p was down-regulated in the echinomycin-treated PD cellular model [ 123 ]. miR-200c-3p was positively correlated with HbA1c [ 106 ].…”

Section: Microrna Biomarkersmentioning

confidence: 99%

MicroRNAs, Parkinson’s Disease, and Diabetes Mellitus

Wang

2021

IJMS

View full text Add to dashboard Cite

Parkinson’s disease (PD) is a neurodegenerative disorder that affects 1% of the population over the age of 60. Diabetes Mellitus (DM) is a metabolic disorder that affects approximately 25% of adults over the age of 60. Recent studies showed that DM increases the risk of developing PD. The link between DM and PD has been discussed in the literature in relation to different mechanisms including mitochondrial dysfunction, oxidative stress, and protein aggregation. In this paper, we review the common microRNA (miRNA) biomarkers of both diseases. miRNAs play an important role in cell differentiation, development, the regulation of the cell cycle, and apoptosis. They are also involved in the pathology of many diseases. miRNAs can mediate the insulin pathway and glucose absorption. miRNAs can also regulate PD-related genes. Therefore, exploring the common miRNA biomarkers of both PD and DM can shed a light on how these two diseases are correlated, and targeting miRNAs is a potential therapeutic opportunity for both diseases.

show abstract

Section: Microrna Biomarkersmentioning

confidence: 99%

MicroRNAs, Parkinson’s Disease, and Diabetes Mellitus

Wang

2021

IJMS

View full text Add to dashboard Cite

show abstract

“…Its expression has been reported to be significantly downregulated in serum of patients with AD. It has also been demonstrated to promote inflammatory response of cells via increased expression of TLR2 gene [6]. The aim of this research was to study the regulatory mechanism of miR-146a on MPTP-induced neuroinflammation in PD mice.…”

Section: Introductionmentioning

confidence: 99%

Regulatory mechanism of miR-146a on MPTP-induced neuroinflammation in mice with Parkinson's disease

Cao¹,

Guo²,

Mochizuki³

et al. 2022

Trop. J. Pharm Res

View full text Add to dashboard Cite

Purpose: To study the regulatory influence of microRNA-146a (miR-146a) on 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine (MPTP)-induced neuroinflammation in mice with Parkinson's disease (PD). Methods: Forty specific pathogen-free (SPF) male C57BL/6 mice were divided into 2 groups: normal control and PD groups. The 2 groups were each divided into 2 subgroups: miR-146a inhibitor and inhibitor control groups. The mRNA and protein expressions of miR-146a, interleukin-1 receptor- associated kinase-1 (IRAK-1) and P65-NF-κB were determined by quantitative real-time polymerase chain reaction (qRT-PCR) and immunoblot assay, respectively. Levels of interleukin (IL)-1, IL-6 and TNF-α were assayed by enzyme-linked immunosorbent assay (ELISA). Results: The level of expression of miR-146a was significantly and time-dependently increased in PD mice, relative to control (p < 0.05). In PD group, mRNA and protein expressions of IRAK-1 were markedly higher in miR-146a inhibitor group than in inhibitor control (p < 0.05). Protein expression of P65-NF-κB was significantly upregulated in brains of PD mice, relative to normal mice (p < 0.05). Moreover, IL-1, IL-6 and TNF-α levels were significantly higher in brains of PD mice than in control. Conclusion: These results show the involvement of miR-146a in the etiology of PD, and that its regulation of neuroinflammation occurs via inhibition of IRAK1 gene expression. This finding may be useful in the development of new anti-PD drugs based on miR-146a.

show abstract